These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 26759237)

  • 1. RASSF1A Suppresses the Invasion and Metastatic Potential of Human Non-Small Cell Lung Cancer Cells by Inhibiting YAP Activation through the GEF-H1/RhoB Pathway.
    Dubois F; Keller M; Calvayrac O; Soncin F; Hoa L; Hergovich A; Parrini MC; Mazières J; Vaisse-Lesteven M; Camonis J; Levallet G; Zalcman G
    Cancer Res; 2016 Mar; 76(6):1627-40. PubMed ID: 26759237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NDR2 kinase contributes to cell invasion and cytokinesis defects induced by the inactivation of RASSF1A tumor-suppressor gene in lung cancer cells.
    Keller M; Dubois F; Teulier S; Martin APJ; Levallet J; Maille E; Brosseau S; Elie N; Hergovich A; Bergot E; Camonis J; Zalcman G; Levallet G
    J Exp Clin Cancer Res; 2019 Apr; 38(1):158. PubMed ID: 30979377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RhoB loss induces Rac1-dependent mesenchymal cell invasion in lung cells through PP2A inhibition.
    Bousquet E; Calvayrac O; Mazières J; Lajoie-Mazenc I; Boubekeur N; Favre G; Pradines A
    Oncogene; 2016 Apr; 35(14):1760-9. PubMed ID: 26148238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternate RASSF1 Transcripts Control SRC Activity, E-Cadherin Contacts, and YAP-Mediated Invasion.
    Vlahov N; Scrace S; Soto MS; Grawenda AM; Bradley L; Pankova D; Papaspyropoulos A; Yee KS; Buffa F; Goding CR; Timpson P; Sibson N; O'Neill E
    Curr Biol; 2015 Dec; 25(23):3019-34. PubMed ID: 26549256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repression of YAP by NCTD disrupts NSCLC progression.
    Guo J; Wu Y; Yang L; Du J; Gong K; Chen W; Dai J; Li X; Xi S
    Oncotarget; 2017 Jan; 8(2):2307-2319. PubMed ID: 27903989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TGF-β Targets the Hippo Pathway Scaffold RASSF1A to Facilitate YAP/SMAD2 Nuclear Translocation.
    Pefani DE; Pankova D; Abraham AG; Grawenda AM; Vlahov N; Scrace S; O' Neill E
    Mol Cell; 2016 Jul; 63(1):156-66. PubMed ID: 27292796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RHOB expression controls the activity of serine/threonine protein phosphatase PP2A to modulate mesenchymal phenotype and invasion in non-small cell lung cancers.
    Calvayrac O; Pradines A; Favre G
    Small GTPases; 2018 Jul; 9(4):339-344. PubMed ID: 27676292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circ_0078767 suppresses non-small-cell lung cancer by protecting RASSF1A expression via sponging miR-330-3p.
    Chen T; Yang Z; Liu C; Wang L; Yang J; Chen L; Li W
    Cell Prolif; 2019 Mar; 52(2):e12548. PubMed ID: 30507050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression.
    Burbee DG; Forgacs E; Zöchbauer-Müller S; Shivakumar L; Fong K; Gao B; Randle D; Kondo M; Virmani A; Bader S; Sekido Y; Latif F; Milchgrub S; Toyooka S; Gazdar AF; Lerman MI; Zabarovsky E; White M; Minna JD
    J Natl Cancer Inst; 2001 May; 93(9):691-9. PubMed ID: 11333291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
    Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
    Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A role for RASSF1A in tunneling nanotube formation between cells through GEFH1/Rab11 pathway control.
    Dubois F; Jean-Jacques B; Roberge H; Bénard M; Galas L; Schapman D; Elie N; Goux D; Keller M; Maille E; Bergot E; Zalcman G; Levallet G
    Cell Commun Signal; 2018 Oct; 16(1):66. PubMed ID: 30305100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RASSF1A controls tissue stiffness and cancer stem-like cells in lung adenocarcinoma.
    Pankova D; Jiang Y; Chatzifrangkeskou M; Vendrell I; Buzzelli J; Ryan A; Brown C; O'Neill E
    EMBO J; 2019 Jul; 38(13):e100532. PubMed ID: 31268606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RhoB is frequently downregulated in non-small-cell lung cancer and resides in the 2p24 homozygous deletion region of a lung cancer cell line.
    Sato N; Fukui T; Taniguchi T; Yokoyama T; Kondo M; Nagasaka T; Goto Y; Gao W; Ueda Y; Yokoi K; Minna JD; Osada H; Kondo Y; Sekido Y
    Int J Cancer; 2007 Feb; 120(3):543-51. PubMed ID: 17096327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant methylation of RASGRF2 and RASSF1A in human non-small cell lung cancer.
    Chen H; Suzuki M; Nakamura Y; Ohira M; Ando S; Iida T; Nakajima T; Nakagawara A; Kimura H
    Oncol Rep; 2006 May; 15(5):1281-5. PubMed ID: 16596198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RASSF1A-mediated regulation of AREG via the Hippo pathway in hepatocellular carcinoma.
    Ahn EY; Kim JS; Kim GJ; Park YN
    Mol Cancer Res; 2013 Jul; 11(7):748-58. PubMed ID: 23594797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic value of methylation status of RASSF1A gene as an independent factor of non-small cell lung cancer].
    Zhang H; Zhang S; Zhang Z; Jia H; Gu S; Zhao D
    Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):311-6. PubMed ID: 20677556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma.
    Byun DS; Lee MG; Chae KS; Ryu BG; Chi SG
    Cancer Res; 2001 Oct; 61(19):7034-8. PubMed ID: 11585730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
    Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
    Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RASSF1A is not appropriate as an early detection marker or a prognostic marker for non-small cell lung cancer.
    Choi N; Son DS; Song I; Lee HS; Lim YS; Song MS; Lim DS; Lee J; Kim H; Kim J
    Int J Cancer; 2005 Jul; 115(4):575-81. PubMed ID: 15700308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
    Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
    Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.